What specific group of patients are given sapropterin?

Who is eligible for sapropterin treatment?

Sapropterin is typically prescribed to patients with Phenylketonuria (PKU), a rare genetic disorder that affects the body's ability to break down the amino acid phenylalanine (Phe).

What is PKU, and how dose sapropterin work?

PKU is caused by a deficiency in the enzyme phenylalanine hydroxylase (PAH), which is responsible for converting Phe into tyrosine. Patients with PKU have high levels of Phe in their blood, which can lead to developmental delays, intellectual disability, and other complications if left untreated.

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), a cofactor required for PAH to function correctly. By providing the necessary BH4, sapropterin reduces Phe levels in the blood, allowing patients with PKU to manage their condition more effectively [1].

Who is eligible for sapropterin treatment?

According to the Food and Drug Administration (FDA), sapropterin is indicated for use in patients with PKU who have the following characteristics:

* A mild to moderate deficiency in PAH activity
* Elevated Phe levels in the blood
* A response to sapropterin as evidenced by a decrease in Phe levels

Eligibility for sapropterin treatment is determined on a case-by-case basis and is typically based on the results of a BH4 loading test, which assesses the patient's response to sapropterin [2].

Important information about sapropterin and PKU

It is essential to note that sapropterin is not a cure for PKU and is used in conjunction with a strict diet that restricts Phe intake to prevent high levels of the amino acid in the blood [3].

For more information on sapropterin and PKU, please visit the FDA website and DrugPatentWatch.com [4].

Sources

[1] Food and Drug Administration. (2010). Kuvan (sapropterin dihydrochloride) label.

[2] American Academy of Pediatrics. (2018). Phenylketonuria: Recommendations for Diagnosis and Management.

[3] Genetic and Rare Diseases Information Center. (2022). Phenylketonuria.

[4] DrugPatentWatch.com. (2023). Sapropterin.